The Conversation (0)
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
Feb. 23, 2018 09:12AM PST
Life Science Investing NewsLa Jolla Pharmaceutical (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress. As quoted in the press release: “2017 was an exciting year for La Jolla, …
La Jolla Pharmaceutical (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress.
As quoted in the press release:
“2017 was an exciting year for La Jolla, highlighted by the FDA’s approval of GIAPREZA,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “We are excited to bring this new treatment option to the many critically ill patients suffering from septic or other distributive shock.”